SKYE241220P10000
- 0.00
- 0.000.00%
SKYE BIOSCIENCE INC Newsroom
Give the Gift of Emotional Growth This Holiday Season
Insider Sale: Chief Development Officer of $SKYE (SKYE) Sells 19,489 Shares
Skye Bioscience to Participate in Upcoming December Healthcare Investment Conferences
Craig-Hallum Maintains SKYE BIOSCIENCE INC(SKYE.US) With Buy Rating
Express News | Skye Bioscience Inc - Expects Interim Data for Cbeyond Phase 2 Trial in Q2 2025
Skye Bioscience Surpasses 50% Patient Enrollment in Phase 2 Obesity Study of Differentiated CB1 Inhibitor
Oppenheimer Maintains SKYE BIOSCIENCE INC(SKYE.US) With Buy Rating, Maintains Target Price $21
Express News | Skye Bioscience Shares Are Trading Higher After the Company Reported Better-than-expected Q3 EPS Results
Skye Bioscience GAAP EPS of -$0.10 Beats by $0.15
SKYE BIOSCIENCE INC | 10-Q: Q3 2024 Earnings Report
SKYE BIOSCIENCE INC | 8-K: Skye Bioscience Reports Third Quarter 2024 Financial Results and Recent Highlights
Press Release: Skye Bioscience Reports Third Quarter 2024 Financial Results and Recent Highlights
Skye Bioscience Q3 2024 Earnings Preview
Piper Sandler Maintains SKYE BIOSCIENCE INC(SKYE.US) With Buy Rating, Maintains Target Price $20
Scotiabank Maintains SKYE BIOSCIENCE INC(SKYE.US) With Buy Rating, Maintains Target Price $20
Skye Bioscience Demonstrates Prominent Role of Peripheral CB1 Inhibition and Achieves Significant Weight Loss With Novel CB1-inhibiting Antibody, Nimacimab, in Preclinical Model
Earnings Preview: SKYE to Report Financial Results Post-market on November 07
Express News | Skye Bioscience Names Independent Director Paul Grayson as Chairman of the Board
Press Release: Skye Bioscience Names Independent Director Paul Grayson as Chairman of the Board
Skye Bioscience to Participate in Upcoming November Healthcare Investment Conferences